Induction of cul-Acid Glycoprotein by Recombinant Human Interleukin ...

Vol .263, NO. 15. Issue of May 25, pp. 7141-7146, 1988

CHEMISTRY THEJOURNALOF BIOLOGICAL

Printed in U.S. A .

0 1988 by The American Society for Biochemistry and Molecular Biology, Inc.

Induction of cul-Acid Glycoprotein by RecombinantHuman Interleukin-1 in Rat Hepatoma Cells* (Received for publication, August 26, 1987)

Thomas Geiger, Tilo Andus, Jan Klapproth, HinnakNorthoff$, and Peter C. HeinrichQ From the Bwchemisches Institut, Uniuersitat Freiburg, Hermann-Herder-Strasse 7, 0-7800 Freiburg and the SBlutspendezentrale des Deutschen Roten Kreuzes, Oberer Eselsberg,0-7900 Ulm, Federal Republic of Germany

The induction of al-acid glycoprotein mRNA by recombinant murine interleukin- 1, recombinant human interleukin- l a , and recombinant human interleukin18 has been studied in the rat hepatoma cell line Fao. Whereas the stimulatory capacities of recombinant human interleukin- l a and recombinant murine interleukin-1 were almost identical, the concentrations of recombinant humaninterleukin- 18 needed for half-maximal induction of al-acid glycoprotein mRNA were lower by three orders of magnitude. A 60-fold increase in al-acid glycoprotein mRNA levels was observed 18 h after the addition of recombinant interleukin-18. In parallel albumin mRNAlevels decreased to about 30%. The al-acid glycoprotein mRNA induction was strictly dependent on the presence of dexamethasone. For a full stimulation dexamethasone concentrations of >lo-’ M were needed, whereas concentrations of M were ineffective. The increase in al-acid glycoprotein mRNA after recombinant human interleukin-18 was followed by a 36-fold stimulation in al-acid glycoprotein synthesis and secretion. When protein synthesis was blocked by either cycloheximide, puromycin, or emetine, the induction of al-acid glycoprotein mRNA by recombinant human interleukin- 18 wasimpaired suggesting the involvement of a short-€ivedprotein in the induction of al-acid glycoprotein mRNA.

Tissue injury and inflammatory processes induce a host response commonly referred to as the acute-phase reaction (1).The acute-phase response is characterized by a series of complex localand systemic reactions. Among the latter,drastic changes in the serum levels of acute-phase proteins are observed. In the rat a,-macroglobulin, al-acid glycoprotein (aI-AGP),’ and cysteine proteinase inhibitor represent the major positive acute-phase reactants. Their serum levels are elevated between 10- and several hundred-fold during inflammation (reviewed in Refs. 1-3). The increase in serum levels is preceded by an increase in.the respective mRNA levels (410). A t the same time serumand mRNA levelsof the negative *This workwas supported by grants from the Deutsche Forschungsgemeinschaft, Bonn, and the Fonds der Chemischen Industrie, Frankfurt. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “aduertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 5 To whom reprint requests should be addressed Biochemisches Institut, Hermann-Herder-Str. 7, D-7800 Freiburg, F. R. G. ’ The abbreviations used are: a,-AGP, orl-acid glycoprotein; 11-1, interleukin-1; rh11-la, recombinant human interleukin-la; rh11-16, recombinant human interleukin-la; rm11-1, recombinant murine interleukin-1.

acute-phase proteins albumin, transferrin, transthyretin, or al-inhibitor 3 decrease (11-14). These changes are caused by the action of inflammatory mediators secreted by mononuclear phagocytes (15-19). Among the monokines 11-1 (for reviewsseeRefs.20-22), tumor necrosis factor-a (23, 24) and hepatocyte-stimulating factor (18, 19, 25-29) have been found to be stimulants of acute-phase protein synthesis. For a long time 11-1 has been favored as themajor mediator of acute-phase protein synthesis (20). Moreover, recombinant 11-1 has been available for a few years (30-34). Nevertheless, in only a few systems has acute-phase protein stimulation by 11-1 been demonstrated. Thus far however, recombinant 11-1 has not been shown to induce the full spectrum of acute-phase protein synthesis as found i n vivo during inflammation. Only a few of the acutephase proteins investigated were inducible by 11-1 (23, 24,35, 36). Furthermore, the changes in acute-phase protein synthesis caused by11-1 added to cell cultures were much weaker than those found i n vivo during the acute-phase response (23, 24, 35, 36). Hence, a suitable i n vitro system to study the action of 11-1on the synthesis of acute-phase proteins has not been available. In the present paper we describe that recombinant murine 11-1, and recombinant human 11-la and p change albumin, and al-AGP mRNA levels in a well-differentiated rat hepatoma cell line to a similar extent as i n vivo during experimental inflammation. MATERIALS ANDMETHODS

Chemicals-~-[~~S]Methionine(>lo00 Ci/mmol) and deoxycytidine 5’-[a-32P]triphosphate (>3000 Ci/mmol) were purchased from Amersham Buchler (Braunschweig,Federal Republic of Germany (F. R. G.)). Cycloheximide, puromycin, and emetine were from Sigma (Munich, F. R. G.). RNase-free DNase I was from Pharmacia LKB Biotechnologies Inc. (Freiburg, F. R. G.). Recombinant murine interleukin-1 and recombinant human interleukin-la weregenerously supplied by Drs. P. Lomedico and A. Stern (Hoffmann-LaRoche, Nutley, NJ). Recombinant human interleukin-la was from Biogen (Geneva, Switzerland). Lipopolysaccharide from Salmonella abortus equi was a generous gift of Dr. C. Galanos, Max-Planck Institut fur Immunbiologie (Freiburg, F. R. G.). AlbumincDNAwas kindly supplied by Dr. A. Alonso, DKFZ (Heidelberg, F. R. G.), a,-AGP cDNA by Dr. G. Schreiber (Melbourne, Australia), and the genomic clone of rRNA by Dr. I. Grummt (Wurzburg, F. R. G.). The Fao cell line established and characterized by Deschatrette and Weiss (37) was kindly supplied by Dr. F. Wiebel, Gesellschaft fur Strahlenforschung (Munich, F. R. G.). Culture and Labeling of Fa0 Cells-Fao cells were grown in RPMI 1640 mediumcontaining 5% fetal calf serum (Sigma), 100 mg/liter of streptomycin and 65 mg/liter of penicillin, and passaged twicea week by trypsinization. For most experiments the cells were plated on a 24-well dish (Falcon 3047) 2 days earlier. About 5 X lo6 cells/well were used for the cytoblots. For the radioactive labeling of a,-AGP 50 pCi of [35S]methioninewere added to 2 X lo6 cells for 3 h. Immunoprecipitation-Immunoprecipitations were carried out in

7141

Induction of al-Acid Glycoprotein Recombinant by Interleukin-1

7142

the presence of a monospecific anti-al-AGP asdescribed in previous publications (10, 14, 29). Isolation of RNA and Northern Analysis-Cellswerelysedby guanidinium thiocyanate, and RNA was isolated according to the protocol of Chirgwin et al. (38). 15 pg of total RNA was separated on a 1%agarose, 6.6% formaldehyde gel prior to transfer to the gene screen filters (39). Cytoblot and mRNA Hybridization-Cells (5 X 105/well) were lysed in 10 mM Tris-HC1 buffer, pH 7.0, containing 1 mM EDTA, and 1% Nonidet P-40, nuclei were removed bycentrifugation, the cytoplasmic RNA was denatured in the presence of formaldehyde essentially as described by White and Bancroft (40),and RNA was blotted to a gene screen membrane using a Manifold dot-blot apparatus (Schleicher & Schull). After baking the filters at 80 "C for 2 h and prehybridization (39) for 6 h, the filters were hybridized (39) to 32Plabeled cDNA probes. The cDNAs were radioactively labeled using the random primer technique described by Feinberg and Vogelstein (41). Filters were washed 3 times in 0.1 X SSPE, 0.1% sodium dodecyl sulfate a t 55 "C for 30 min (20 X SSPE = 3.6 M sodium chloride, 0.2 M sodium phosphate, 0.02 M EDTA, pH 7.4) (39).

rhIl-lp was about 50% higher than the maximum achieved with rhI1-la orrm11-1. Furthermore, for half-maximal induction rhII-lp is required at concentrations which were lower by three orders of magnitude than thoseof rhI1-la or rm11-1. For comparison we have analyzed the influence of the three interleukinsonthe negative acute-phaseproteinalbumin mRNA levels (Fig. 1B). Dose-dependent decreases were found for rhI1-la or p as well as for rm11-1. Again, rhIl-lP had the strongest effect (filled triangles). Since the recombinant interleukins isolatedfrom E. coli may be contaminated by lipopolysaccharide, it was necessary to exclude that lipopolysaccharide exerts a stimulatory effect on the al-AGP mRNA induction. Lipopolysaccharide in concentrationsranging from 1pg/ml to 10 pg/ml in the presence of M dexamethasone had noeffect on al-AGP mRNA levels in Faocells. Moreover, preincubation of 11-1 with the lipopolysaccharide inactivator polymyxin B (10pg/ml) did not diminish the stimulatory effect of 11-1 (data not shown). RESULTS To study the al-AGP mRNA induction in greater detail, Recombinant 11-la and 11-1p and recombinant murine 11-1 we selected rhI1-1P as inducing agent. Earlier studiesrevealed requires the were compared in respect to their capabilities to induce al- that acute-phase protein induction in the rat AGP mRNA in rat hepatoma cells (Fao). Prior to the additionpermissive action of steroid hormones. We examined the to the hepatoma cell cultures the activities of the three 11-1 effect of the synthetic glucocorticoid analog dexamethasone preparations had been determined in a thymocyte costimula- for the induction of al-AGP mRNA by rhI1-1P. Fig. 2 shows tory assay. It can be seen in Fig. lA that rhI1-la andP as well that the presence of dexamethasone is a prerequisite for alas rmI1-1 causea dose-dependentstimulation of al-AGP AGP mRNA induction. A full stimulation was achieved with M, whereas concenconcentrations of mRNA. Whereas the stimulatory capacities of rhI1-la and dexamethasone M were ineffective. The greatest rmI1-1 were almost identical, rhIl-lpwas even more effective trations of less than (filled triangles). Maximal induction of al-AGP mRNA by influence on the stimulationof al-AGP mRNA synthesiswas alphal AG P

ALBUMIN

B

la

- 1 ' " 0

0.003 0.03 0.3

3

30 300 3000

r e c IL- 1 (units/ml)

0

0.003 0.03 0.3

3

30 300 3000

rec I L - 1 (units/ml)

FIG. 1. Induction of al-acid glycoprotein mRNA by recombinant human interleukin-la, recombinant human interleukin-la, and murine interleukin-1. Fao cells (5 X lo5 cells/well) were incubated with rhI1-la (O),rhI1-1B (A),and rmI1-1 (m) in concentrations indicated in the figure in the presence of M dexamethasone for 18 h. The various concentrations of 11-1were obtained after dilution with RPMI 1640 medium containing 5% fetal calf serum. The cells were lysed, the cytoplasmic RNA extract blotted to a gene screen membrane, and hybridized with 32P-labeled a,-AGP cDNA (A) and albumin cDNA ( B ) . The radioactivity of each dot was determined in a liquid scintillation counter.

Induction of cr,-Acid Glycoprotein by Recombinant Interleukin-I

7143

is evident that the sole addition of dexamethasone does not lead to the induction of al-AGP mRNA synthesis in Fao cells. Thus, Fao cells need the combined actionof dexamethasone and rhIl-lB for al-AGP mRNA induction. Since data obtained from dot-blots may sometimes contain unspecifichybridizationsignals, we studiedtheaI-AGP mRNAinductionandthe decreasein albumin mRNA at different times after the addition of rhIl-lB to Fao cells by Northern analysis. I t can be seen from Fig. 4 that aI-AGP mRNA with a size of about 850 bases increased and that albumin mRNA with a mobility corresponding to a length of about 2100 bases decreased in a time-dependentmanner. There is a rather sharp decrease in albumin mRNA levels between 8 and 12 h. Since the kinetics of al-AGP mRNA 1614 1012 lilo 0 lo6 10" induction does not show such a discontinuity and since the Der ( M ) amounts of 28 S and 18 S rRNA were the samefor the various FIG. 2. Requirement of dexamethasone for the induction of time points, it isunlikely that the sharp decrease in albumin al-acid glycoprotein mRNA by recombinant human interleu- mRNA is due to a difference in RNA added to the gel. 20 h kin-10. Fao cells (5 X IO5cells/well) were incubated with 500 units/ ml of rhI1-10 in the presence of increasing concentrations of dexa- after rhIl-lB al-AGP mRNA levels were elevated about 56methasone for 18 h. The cells were lysed, the cytoplasmic RNA fold over the basallevel as determined by counting theradioextract blotted to a gene screen membrane, and hybridized with :i2P- activity of the excised bands. This increase could either be labeled al-AGP cDNA. The radioactivity of each dot was determined the result of an increased synthesis,a decreased degradation in a liquid scintillation counter. of al-AGP mRNAor a combination of both processes. T o examine whether the al-AGP mRNA induction requires ongoing protein synthesis, we have studied the effect of various inhibitors of protein synthesis on their influence on alAGP mRNA induction. When cycloheximide, puromycin, or emetine were added in increasing concentrations to the culture media of Fao cells, total protein synthesis was blocked to about95-98% (Fig. 5,A-C, filled circles). In parallel to the inhibition of proteinsynthesis,theinduction of al-AGP mRNA was impaired (filled triangles). It is interesting that theal-AGPmRNAinduction was moresensitive to low

28S0

5

10

15

20 time ( h )

25

30

35

FIG.3. Time course of theinduction of al-acid glycoprotein mRNA by recombinant human interleukin-10. Fao cells (5 X lo5cells/well) were incubated in the presence of IO-' M dexamethasone without (B) or with 500 units of rhII-l~/ml(0)for the times indicated in the figure. The cells were lysed, the cytoplasmic RNA extract blotted to a gene screen membrane, and hybridized with "Plabeled al-AGP cDNA. The radioactivity of each dot was determined in a liquid scintillation counter.

found between and 10"' M dexamethasone. T o gain some information on the kinetics of al-AGP mRNA induction by rh11-lB, Fao cells were exposed to rhI1-1B for varying lengths of time (Fig. 3). Although hardly visible in the figure, already 2 h after the addition of 500 units/ml an increase in al-AGP mRNA levels was observedwhen the radioactivity of the respective dot was quantitated. Maximal stimulation was found at 18 h followed by a rather steep decrease. Bymeasuring the radioactivity of the dots,we found a 60-fold increase in al-AGP mRNA18 h after rhIl-lB. Since it is known that aI-AGP is inducible by dexamethasone alone in rat hepatocytes (42), we measured, ina parallel experiment, the kinetics of al-AGP mRNA induction in the presence of lod6M dexamethasone but withoutrhI1-18 (filled squares).I t

3

albumin

. a,AGP

0

4

8

12

16

20

24

time [h]

FIG.4. Northern analysis of mRNA levels for al-acid glycoprotein and rat serum albumin at different times after addition of recombinant human interleukin-10. Fao cells (5 X 10" cells/dish) were stimulated with rhI1-16 (500 units/ml) in the M dexamethasone. A t the times indicated total RNA presence of was extracted as described under "Materials and Methods." For each time point 15 pg of total RNA wereseparated on a denaturingagarose gel and blotted to a gene screen transfer membrane. The RNA was hybridized to a mixture of "P-labeled rat serum albumin and a,-AGP cDNAs as detailed under "Materials and Methods."

Induction of al-Acid Glycoprotein by Recombinant Interkukin-1

7144

0 02

05

2

1

0 5 10 15

60

30

0

10

20

30

Em (pg/ml I

Pura ( p w n l )

C H X (pg/ml)

FIG. 5. Effect of various inhibitors of protein synthesis on the induction of al-acid glycoprotein mRNA by recombinant human interleukin-18. Fao cells (5 X 10' cells/well) were preincubated with cycloheximide ( A ) ,puromycin ( B ) ,and emetine ( C ) in the concentrations indicatedin the figure for 1 h, and 500 units of rhIl-lp/ml were then added. 1O"j M dexamethasone was present during the preincubation and the incubation period. After 18 h the cells were lysed, the cytoplasmic RNA extract blotted to a gene screen membrane and The radioactivity of each dot was determined in a liquid scintillation hybridized with 32P-labeled a,-AGP cDNA. counter. Inhibition of protein synthesis was determined in a parallel experiment by measuring the incorporation of 10 pCi of [35S]methionine/5X lo6 cells into trichloroacetic acid-precipitable material during a 3-h labeling

period in methionine-free-medium.

be deceiving, we have quantifiedtheamounts of al-AGP 1 of rhIl-18 to Fao secreted at different times after the addition cells. Fig. 6 shows that uninduced Faocells synthesized and secreted 60.8 ng, whereas 21 h after rhI1-1P 29 ng of al-AGP/ lo6 cells/h (about 36-fold increase) were secreted. It should be noted that rhI1-1B led to a 2-3-fold stimulation of secretion of total protein into themedium. DISCUSSION

0

5

10

15

20

25

Time (h)

FIG. 6. crl-Acid glycoproteinsynthesis and secretion atdifferent timesafter rhI1-18 treatment of Fao cells. Fao cells ( 2 X

lo6 cells/well) were incubated in the presence of M dexamethasone with500 units of rhIl-lp/ml for the times indicated in the figure. 3 h prior to the a,-AGP determinations, the medium was changed, and the cells were labeled with 50 pCiof [33S]methionine in the presence of 500 units of rhIl-lfl/ml. The absolute amounts of the secreted a,-AGP were determinedby a radioimmunoassay. Increasing amounts of unlabeled al-AGP were mixed with 100 pl of medium containing the [35S]methionine-labeled a,-AGP and allowed to compete for binding to a limited amount of a monospecific antiserum against a,-AGP. inhibitor concentrations than total protein synthesis. Thus, the induction of al-AGP mRNA byrhI1-18 requires ongoing protein synthesis. Since relative measurementsof al-AGP mRNA levels may

The comparison of rhI1-la, rh11-18, and rmI1-1 has shown that a,-AGP mRNAis induced by all threespecies. However, rhIl-lp exhibited a much stronger stimulatory effect than rh11-la or rm11-1. This observation correlates with the fact that mI1-1 and hI1-lahave the sameisoelectric point of about 5, whereas hI1-18 has anisoelectric point of 7.0 (22). Furthermore, the amino acid sequence homologies between hI1-la and mI1-1 are 62%,between hI1-la and hIl-1fl only 26%, and between hI1-18 and mI1-1 only 30% (32). Nevertheless, the difference in the activities of the three 11-1 preparations is surprising, since until now differences in receptor binding could not be observed for 11-la and Il-lP in T lymphocytes (43), fibroblasts (44-46), and EBV-transformed B-iymphocytes (47).Possible explanations for the different inducing capabilities of the three 11-1preparations tested in Fao cells could be either different affinities to the same receptor or even the existenceof two different receptors. We estimated half-maximal stimulation of al-AGP mRNA in Faocells at rhI1-18 concentrations of about 0.6 pM, reflecting a specific interaction of rhI1-18 with rat hepatoma cells. Concentrations of human recombinant 11-16 of 0.05-34 phf and 2-50 PM have been determined for T lymphocytes and fibroblasts, respectively (44,45,47-51). In the present paper we demonstrate that 11-1 induced mRNA for al-AGP in rat hepatoma cells to an extent comin vivo during inflammation (8, 13). parable to the one found 11-1 was reported t o induce severalacute-phase proteins in rat hepatocyte primary cultures. Previously, we described a%fold

Induction of crl-Acid Glycoprotein by Recombinant Interleukin-1 stimulation of a,-macroglobulin synthesis by murine recombinant 11-1 (19). Ramadori et al. (52) described the induction of serum amyloid A and factor B by murine recombinant 11-1 in vivo and in hepatocyte primary cultures from mice. Increases in thesynthesis of a,-antichymotrypsin, factor B and C3, but not C2, C4, and al-proteinaseinhibitor were observed in Hep3B cells upon addition of human recombinant 11-1(24). Using HepG2 cells, Karin et al. (53) induced metallothionein mRNA by recombinant murine 11-1. As in the case of tumor necrosis factor a, Darlington et al. (23) reported that among several acute-phase proteins tested in Hep3B2 cells mouse recombinant 11-1 induced only the synthesis ofC3. In rat hepatocytes Fuller et al. (27) did not observe any stimulation of fibrinogen synthesis by murine recombinant 11-1. From the fact that some acute-phase proteins areinducible by 11-1,whereas others are not,it is evident that 11-1functions as a mediator in acute-phase protein induction but not as a universal one. Recent work byBaumann et al. (54) has clearly shown that 11-1 induces only a subsetof acute-phase proteins, namely C3, haptoglobin, and al-AGP,whereas another subset of acute-phase proteins is regulated by hepatocyte-stimulating factor. It is of interest to note that in the Fao cells used in this study al-AGP mRNA induction required the combined action of Il-lp and dexamethasone. This is in contrast to the data obtainedin other systems, i.e. in rat hepatocyte primary cultures(42),in HTC rat hepatoma cells (55), in L-cells transfected with the a,-AGP gene (56) or in rats in vivo (57) where the sole addition of dexamethasone led to a stimulation of a,-AGP.mRNA synthesis. On the otherhand, in thecases of human cell lines such as HepG2 or Hep3B (23,24) aswell as in mouse hepatocytes or in mice (52) acute-phase protein induction by Il-lp was achieved without additionof glucocorticoids. Using the combination of 11-la and dexamethasone a 60fold increase in cytoplasmic mRNA levels of a,-AGP was observed. This increase could not be accounted for by the measurements of transcriptionrates, where essentially no increases were found (data not shown). Thus, the increase in al-AGP mRNA concentrations mustbe due to post-transcriptional mechanisms, such as stabilization of the pre-mRNA for al-AGP, facilitated nucleocytoplasmic transport, or increase in the half-life of cytoplasmic a,-AGP mRNA. We like to favor the first mechanisms, since nuclei from unstimulated cells show high transcription rates, but at the same time no cytoplasmic al-AGP mRNA can be detected. When al-AGP mRNA degradation was measured after blocking RNA synthesis by actinomycin D, we did not find anyindication for a difference inthe degradation rates of al-AGP mRNA in stimulated and unstimulated Fao cells (data not shown). Thus, theelevated al-AGP mRNA levels after stimulation of Fao cells with Il-lp are not due to a reduced degradation. On the other hand, reduction in degradation of mRNA has been described to play a role during the stimulation of several proteins, such as ovalbumin and conalbumin (58), serum amyloid A (59),malic enzyme (60, and insulin (61). Our data are similar to thefindings of Vannice et al. (62) who observed essentially no increase in transcription rates in HTC cells after dexamethasone, whereas cytoplasmic RNA increased about 100-fold (55). In contrast tothese data Kulkarni et al. (57) observed a 30-40-fold stimulation in the al-AGP transcription rate in normal and in adrenalectomized rats after the administration of dexamethasone. We have demonstrated thatthe induction of al-AGP mRNA byrhI1-10 is prevented when proteinsynthesis is inhibited. This finding is an indication 'for the involvement

7145

of a short-lived protein in a,-AGP mRNA induction. Vannice et al. (55), Reinke and Feigelson (56), and Klein et al. (63) have also described the requirement of ongoing protein synthesis for the induction of al-AGP mRNA. a,-Uteroglobulin (64), tryptophan oxigenase (65), ovalbumin, conalbumin (66), a-fetoprotein (67) represent further examples, where protein synthesis is needed for induction. On the other hand, the stimulation of fibrinogen and a,-antichymotrypsin by conditioned media from human monocytes was unaffected by inhibitors of protein synthesis (27, 28). Interestingly, various systems have been described, where inhibition of protein synthesis has a stimulatoryeffect on mRNA synthesis. Probably due to the loss of short-lived repressors, tyrosine aminotransferase (68), tumor necrosis factor-a and 11-1 (69), interferon-pl (70), and interferon-p2 (71) are well-documented examples for this kind of regulation. In conclusion, in the present paper a well-defined in vitro system suitable for the study of acute-phase induction of 11l p has been presented. Acknowledgments-We are indebted to Dr. F. Wiebel(Munich) for supplying us with the Fao cells. Wealso thank M. David for excellent technical assistance and H. Gottschalk for her help with the preparation of this manuscript. REFERENCES 1. Koj, A. (1974) in Structure and Function of Plasma Proteins (Allison,A. C., ed) Vol. 1, pp. 73-125, Plenum Publishing Corp., London 2. Kushner, I. (1982) Ann. N. Y.Acad. Sci. 389,39-48 3. Schreiber, G., and Howlett, G. (1983) in Plasma ProteinSecretion by the Liver (Glauman, H., Peters, T., Jr., and Redman, C., eds) pp. 423-449, Academic Press, London 4. Chandra, T., Kurachi, K., Davie, W. E., and Woo, S. L. (1981) Biochem. Biophys. Res. Commun. 103,751-758 5. Haugen, T. H., Hanley, J. M., and Heath, E. C. (1981) J. Biol. Chem. 256,1055-1057 6. Morrow, J. F., Stearman, R. S., Petzman, C. G., and Potter, D. A. (1981) Proe. Natl. Acad. Sci. U. S. A. 78,4718-4722 7. Princen, J. M. G., Niewenhuizen, W., Mol-Backx, F. P. B.M., and Yap, S. H. (1981) Biochem. Bwphys. Res. Commun. 102, 717-723 8. Ricca, G.A., Hamilton, R. W., McLean, J. W., Conn, A., Kalinyak, J. E., and Taylor, J. M. (1981) J. Biol.Chem. 2 5 6 , 10362-10368 9. Northemann, W., Andus, T., Gross, V., Nagashima, M., Schreiber, G., and Heinrich, P. C. (1983) FEBS Lett. 161,319-322 10. Northemann, W., Andus, T., Gross, V., and Heinrich, P. C. (1983) Eur. J. Biochem. 137,257-262 11. Gauthier, F., and Ohlsson, K. (1978) Hoppe-Seyler's Z. Physiol. Chem. 359,987-992 12. Schreiber, G., Aldred, A. R., Thomas, T., Birch, H. E., Dickson, P. W., Fu, G.-F., Heinrich, P. C., Northemann, W., Howlett, G. J., de Jong, F. A., and Mitchell, A. (1986) Inflammation 1 0 , 59-66 13. Birch, H. E., and Schreiber, G. (1986) J.Biol. Chem. 261,80778080 14. Geiger, T., Lamri, Y., Tran-Thi, T.-A., Gauthier, F., Feldman, G., Decker, K., and Heinrich, P. C. (1987) Biochem. J. 2 4 5 , 493-500 15. Selinger, M. J., McAdam, K. P. W. J., Kaplan, M. M., Sipe, J. D., Vogel, N.,and Rosenstreich, D. L. (1980) Nature 285,498500 16. Fuller, G.M., and Ritchie, D.G. (1982) Ann. N. Y. Acad. Sci. 389,308-322 17. Baumann, H., Jahreis, G. P., Sauder, D. N., and Koj, A. (1984) J. Biol. Chem. 2 5 9 , 7331-7342 18. Koj, A,, Gauldie, J., Regoeczi, E., Sauder, D. N., and Sweeney, G. D. (1984) Biochem. J. 224,505-514 19. Bauer, J., Weber, W., Tran-Thi, T.-A., Northoff, G.-H., Decker, K., Gerok, W., and Heinrich, P. C. (1985) FEBS Lett. 190, 271-274 20. Dinarello, C. A. (1984) New Engl. J.Med. 3 1 1 , 1413-1418 21. Sipe, J. D. (1985) in The Acute Phase Response to Injury and

7146

Induction of al-Acid Glycoprotein Recombinant by Interleukin-1

Infection (Koj, A., and Gordon, A. H., eds) pp. 23-35, Elsevier 44. Dower, S. K., Call, S. M., Gillis, S., and Urdal, D. L. (1986) Proc. Scientific Publishing Co., Amsterdam Natl. Acad. Sci. U. S. A. 8 3 , 1060-1064 22. Oppenheim, J. J., Kovacs, E. J., Matsushima, K., and Durum, S. 45. Chin, J., Cameron, P. M., Rupp, E., and Schmidt, J. A. (1987) J . K. (1986) Immunol. Today 7,45-56 Med. Exp. 165,70-86 23. Darlington, G. J., Wilson, D. R., and Lachman, L. B. (1986) J. 46. Bird, T. A., and Saklatvala, J. (1986) Nature 324, 263-266 Cell Biol. 103,787-793 47. Matsushima, K., Akahoshi, T., Yamada, M., Furutani, Y., and 24. Perlmutter, D. H., Dinarello, C.A., Punsal, P. I., and Colten, H. Oppenheim, J. J. (1986) J. Immunol. 136,4496-4502 R. (1986) J. Clin. Invest. 7 8 , 1349-1354 48. Cameron, P. M., Limjuco, A., G. Chin, J., Silberstein, L., and 25. Bauer, J., Birmelin, M., Northoff, G.-H., Northemann, W., TranSchmidt, J. A. (1986) J. Exp.Med. 164,237-250 Thi, T.-A., Ueberberg, H., Decker, K., and Heinrich, P. C. 49. Rupp, E. A., Cameron, P. M., Ranawat, C. S., Schmidt, J. A., and (1984) FEBS Lett. 177,89-94 Bayne, K. E. (1986) J. Clin. Invest. 78,836-839 26. Woloski, B.M.R. N. J., and Fuller, G. M. (1985) Proc. Natl. 50. Wingfield, P., Payton, M., Tavernier, J., Barnes, M., Shaw, A,, Acad. Sci. U. S. A. 82,1443-1447 Rose,K., Simona, M. G., Demczuk, S., Williamson, K., and 27. Fuller, G.M., Otto, J. M., Woloski, B. M., McGary, C. T., and Dayer, J.-M. (1986) Eur. J. Biochem. 160,491-497 Adams, M.A. (1985) J. Cell Biol. 1 0 1 , 1481-1486 51. Tocci, M. J., Hutchinson, N. I., Cameron, P. M., Kirk, K. E., 28. Baumann, H., Hill, R. E., Sauder, D. N., and Jahreis, G. P. (1986) Norman, D. J., Chin, J., Rupp, E. A., Limjuco, G. A., BonillaJ. Cell Biol. 1 0 2 , 370-383 Argudo, V. M., and Schmidt, J. A. (1987) J. Immunol. 138, 29. Northoff, H., Andus, T., Tran-Thi, T.-A., Bauer, J., Decker, K., 1109-1114 Kubanek, B., and Heinrich, P. C. (1987) Eur. J. Immunol. 17, 52. Ramadori, G., Sipe, J. D., Dinarello, C.A., Mizel, S. B., and Colten, H.R.Med. (1985) J. Exp. 162,930-942 707-711 30. Lomedico, P. T., Gubler, U., Hellmann, C. P., Dukovich, M., Giri, 53. Karin, M., Imbra, R. J., Heguy, A., and Wong, G. (1985) Mol. J. G., Pan, Y.-C. E., Collier, K., Semionow, R., Chua, A. O., Cell. BioZ. 5, 2866-2869 and Mizel, S. B. (1984) Nature 3 1 2 , 458-462 54. Baumann, H., Onorato, V., Gauldie, J.,and Jahreis, G. P. (1987) 31. Auron, P. E.,Webb, A.C., Rosenwasser, L. J., Mucci, S. F., Rich, J.Biol.Chem. 2 6 2 , 9756-9768 A., Wolff, S. M., and Dinarello, C.A. (1984) Proc. Natl. Acad. 55. Vannice, J . L., Ringold, G. M., McLean, J. W., and Taylor, J. M. (1983) DNA 2 , 205-212 Sci. U. S. A. 81,7907-7911 32. March, C. J., Mosley, B., Larsen, A., Cerretti, D.P., Braedt, G., 56. Reinke, R., and Feigelson, P. (1985) J. Biol. Chem. 2 6 0 , 4397Price, B., Gillis, S., Henney, C. S., Kronheim, S. R., Grabstein, 4403 K., Conion, P. C., Hoppe, T. P., and Cosman, D. (1985) Nature 57. Kulkarni, A.B., Reinke, R., and Feigelson, P. (1985) J. Biol. 316,641-646 Chem. 260,15386-15389 33. Furutani, Y., Notake, M., Yamayoshi, M.,Yamagishi, J., Nomura, 58. McKnight, G., and Palmiter, R.D. (1979) J. Biol. Chem. 2 6 4 , H.,Ohue, M., Furuta, R., Fukui, T., Yamada, M., and Naka9050-9058 mura, S. (1985) Nucleic Acids Res. 13,5869-5882 59. Lowell, C. A,, Stearman, R. S., and Morrow, J. F. (1986) J. Biol. 34. Gubler, U., Chua, A. O., Stern, A. S., Hellmann, C. P., Vitek, M.Chem. 261,8453-8461 P., Dechiara, T. M., Benjamin, W. R., Collier, K. J., Dukuvich, 60. Dozin,B., Rall, J. E., and Nikodem, V. M. (1986) Proc. Natl. M., Familletti, P. C., Diedler-Nagy, C., Jenson, J., Kaffka, K., Acad. Sci. U. S. A. 83,4705-4709 Kilian, P. L., Stremlo, D. Wittreich, B. H., Woehle, D., Mizel, 61. Welsh, M., Nielsen, D.A., MacKrell, A. J., and Steiner, D. F. (1985) J. Biol. Chem. 2 6 0 , 13590-13594 S. B., and Lomedico, P. T. (1986) J. Immunol. 136,2492-2497 35. Koj, A., Kurdowska, A., Magielska-Zero, D., Rokita, H., Sipe, J. 62. Vannice, J. L., Taylor, J. M., and Ringold, G. M. (1984) Proc. Natl. Acad. Sci. U. S. A. 81,4241-4245 D., Dayer, J. M., Demczuk, S., and Gauldie, J. (1987) Biochem. Intern. 14,553-560 63. Klein, E. S., Reinke, R., Feigelson, P., and Ringold, G. M. (1987) J. Biol. Chem. 262,520-523 36. Gauldie, J., and Dinarello, C. A. (1987) Immunology 60,203-207 64. Chen, C.-L. C., and Feigelson, P. (1979) Proc. Natl. Acad. Sci. U. 37. Deschatrette.. J.., and Weiss. M. C. (1974) . . Biochimie 56. 1603S. A . 76,2669-2673 1611 38. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, 65. DeLap, L., and Feigelson, P. (1978) Biochem. Biophys. Res. ComW. J. (1979) Biochemistry 18.5294-5299 mun. 82,142-149 39. Maniatis, T., Fritsch, E. F.,-and Sambrock, J. (eds) (1982) Molec- 66. McKnight, G. S. (1978) Cell 14,403-413 ular Cloning,Cold Spring Harbor Laboratory Press, Cold 67. Cook, J. R., and Chin, J.-F. (1986) J. Biol. Chem. 2 6 1 , 46634668 Spring Harbor, NY 40. White, B.A., and Bancroft, F.C. (1982) J. Bwl. Chem. 2 5 7 , 68. Ernest, M. J., DeLap, L., and Feigelson, P. (1978) J. Biol. Chem. 253,2895-2897 8569-8572 41. Feinberg, A. P., and Vogelstein, B. (1983) Anal. Biochem. 132, 69. Collart, M.A., Belin, D., Vassalli, J.-D., de Kossodo, S., and Vassalli, P. (1986) J. Exp. Med. 1 6 4 , 2113-2118 6-13 42. Gross, V., Andus, T., Tran-Thi, T.-A., Bauer, J., Decker, K., and 70. Ringold, G. M., Dieckmann, B., Vannice, J. L., Trahey, M., and McCormick, F. (1984) Proc. Natl. Acad. Sci. U. S. A. 81,3964Heinrich, P. C. (1984) Exp. CeZZRes. 151, 46-54 3968 43. Dower, S. K., Kronheim, S. R., March, C. J., Conlon, P. J., Hopp, T. P., Gillis, S., and Urdal, D. L. (1985) J. Exp. Med. 1 6 2 , 71. Poupart, P., De Wit, L., and Content, J. (1984) Eur. J. Biochem. 143,15-21 501-515